Literature DB >> 18398810

Detection and characterisation of microcirculatory abnormalities in the skin of diabetic patients with microvascular complications.

Belinda A Brooks1, Susan V McLennan, Stephen M Twigg, Dennis K Yue.   

Abstract

The aim of this study was to characterise microvascular blood flow in the skin and to compare it with biomarkers of endothelial dysfunction and tissue inflammation in patients with type 2 diabetes with (n=20) or without (n=20) microvascular complications and 20 control subjects. Microvascular function was measured by laser Doppler velocimetry in combination with iontophoresis of acetylcholine (ACh) and sodium nitroprusside (SNP). Blood was collected for measurement of biomarkers including plasminogen activator inhibitor-1 (PAI-1), soluble intercellular adhesion molecule (sICAM), soluble vascular cell adhesion molecule (sVCAM) and high-sensitivity C-reactive protein (hsCRP). Both ACh and SNP responses fall progressively with the development of diabetes and microvascular complications. For the total cohort, there was a significant overall correlation between ACh and SNP response (r=0.7, p<0.0001), and this relationship was particularly strong in those with microvascular complications. There was a trend towards higher hsCRP levels across the three groups, but no difference in other biomarkers. Abnormalities of microvascular blood flow are evident in diabetes and become more marked with the development of microvascular complications. This relationship was similar to that shown by the marker of inflammation (hsCRP), but stronger than that pertaining to biomarkers of endothelial function. As both ACh and SNP responses are attenuated, the disturbance is not characteristic of endothelial dysfunction alone.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18398810     DOI: 10.3132/dvdr.2008.006

Source DB:  PubMed          Journal:  Diab Vasc Dis Res        ISSN: 1479-1641            Impact factor:   3.291


  7 in total

1.  Quantifying the composition of human skin for glucose sensor development.

Authors:  Willemijn Groenendaal; Golo von Basum; Kristiane A Schmidt; Peter A J Hilbers; Natal A W van Riel
Journal:  J Diabetes Sci Technol       Date:  2010-09-01

Review 2.  Assessing Microvascular Function in Humans from a Chronic Disease Perspective.

Authors:  Alfons J H M Houben; Remy J H Martens; Coen D A Stehouwer
Journal:  J Am Soc Nephrol       Date:  2017-09-13       Impact factor: 10.121

3.  Reliability of lightguide spectrophotometry (O2C) for the investigation of skin tissue microvascular blood flow and tissue oxygen supply in diabetic and nondiabetic subjects.

Authors:  Thomas Forst; Cloth Hohberg; Eda Tarakci; Senait Forst; Peter Kann; Andreas Pfützner
Journal:  J Diabetes Sci Technol       Date:  2008-11

4.  Insulin prevents latent skin lesions by inhibiting the generation of advanced glycation end products in streptozotocin-induced diabetic rats.

Authors:  Xiangfang Chen; Weidong Lin; Shuliang Lu; Yongquan Shi; Junjie Zou; Zhimin Liu; Wanqing Liao
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

5.  Impaired coronary microvascular dilation correlates with enhanced vascular smooth muscle MLC phosphorylation in diabetes.

Authors:  Richard T Clements; Neel R Sodha; Jun Feng; Munir Boodhwani; Yuhong Liu; Shigetoshi Mieno; Kamal R Khabbaz; Cesario Bianchi; Frank W Sellke
Journal:  Microcirculation       Date:  2009-02       Impact factor: 2.628

Review 6.  The association between diabetes and dermal microvascular dysfunction non-invasively assessed by laser Doppler with local thermal hyperemia: a systematic review with meta-analysis.

Authors:  Dagmar Fuchs; Pepijn P Dupon; Laura A Schaap; Richard Draijer
Journal:  Cardiovasc Diabetol       Date:  2017-01-19       Impact factor: 9.951

7.  Neurovascular microcirculatory vasodilation mediated by C-fibers and Transient receptor potential vanilloid-type-1 channels (TRPV 1) is impaired in type 1 diabetes.

Authors:  P Marche; S Dubois; P Abraham; E Parot-Schinkel; L Gascoin; A Humeau-Heurtier; P H Ducluzeau; G Mahe
Journal:  Sci Rep       Date:  2017-03-13       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.